Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Artificial Intelligence-driven, Decentralized Production for Advanced Therapies in the Hospital

Project description

AI for smart therapy provision in hospitals

The EU consortium AIDPATH is dedicated to enable and to augment the next-generation of personalised medicine with gene-engineered immune cells at EU hospitals through the use of AI technology. The exemplary embodiment of gene-engineered immune cells in AIDPATH will be T cells, modified to express a synthetic chimeric antigen receptor (CAR-T), that are already a revolutionary novel treatment in haematology and oncology. AIDPATH will apply AI technology to integrate patient-specific data and biomarkers in CAR-T therapy and to optimise scheduling and resource planning to reduce costs and hospital resource utilisation. The consortium members are well-positioned to engage in a productive dialogue with regulators and patients to ensure acceptance and rapid adoption by EU hospitals and industry.

Objective

AIDPATH (Artificial Intelligence-driven, Decentralized Production for Advanced Thera-pies in the Hospital) is a high-energy EU consortium, dedicated to enable and to augment the next-generation of personalized medicine at EU hospitals through the use of AI tech-nology. The exemplary embodiment of gene-engineered immune cells in AIDPATH will be T cells expressing a synthetic chimeric antigen receptor (CAR-T). These cells are already a revolutionary novel treatment in hematology and oncology, and will also be useful for treating infections and autoimmune diseases. Conventional CAR-T therapy is complicated by complex logistics from centralized manufacturing facilities, inflexible manufacturing and clinical use schemes that disregard patient and cell characteristics, thus limiting patient access and therapeutic outcome.
AIDPATH will apply top-notch AI technology to integrate patient-specific data and biomarkers in CAR-T therapy, and apply flexible manufacturing schemes to obtain CAR-T cell products with optimal fitness and anti-tumor potency. AI technology will be applied in pre- and in-process controls to reduce cost and hospital resource utilization and to augment patient access. AIDPATH will establish a role model that integrates the hospital in a smart manner, incorporating aspects of logistics, capacity planning, data management and cybersecurity by design. The project is designed to enable smart ‘bedside’ provision of personalized treatments and to accomplish end-to-end automation of hospital-based CAR-T manufacture. A key deliverable in AIDPATH will be an integrated cyberphysical infrastructure for rapid dissemination of the ‘smart CAR-T manufacturing and clinical use’ concept to hospitals throughout the EU.
AIDPATH brings together a world-class consortium to address these challenges, consisting of key opinion leaders in science and translational medicine, innovative SMEs and commercial partners, patient advocates, policy makers and regulatory experts.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

IA - Innovation action

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-DT-2018-2020

See all projects funded under this call

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Net EU contribution
€ 2 957 166,25
Address
HANSASTRASSE 27C
80686 Munchen
Germany
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Research Organisations
Links
Total cost
€ 2 957 166,25

Participants (14)